These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 10023511

  • 1. Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa.
    Gianotti L, Rolla M, Arvat E, Belliti D, Valetto MR, Ferdeghini M, Ghigo E, Müller EE.
    Biol Psychiatry; 1999 Feb 01; 45(3):334-9. PubMed ID: 10023511
    [Abstract] [Full Text] [Related]

  • 2. Effects of beta-adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in anorexia nervosa.
    Gianotti L, Arvat E, Valetto MR, Ramunni J, Di Vito L, Maccagno B, Camanni F, Ghigo E.
    Biol Psychiatry; 1998 Feb 01; 43(3):181-7. PubMed ID: 9494699
    [Abstract] [Full Text] [Related]

  • 3. Effects of free fatty acids and acipimox, a lipolysis inhibitor, on the somatotroph responsiveness to GHRH in anorexia nervosa.
    Gianotti L, Fassino S, Daga GA, Lanfranco F, De Bacco C, Ramunni J, Arvat E, MacCario M, Ghigo E.
    Clin Endocrinol (Oxf); 2000 Jun 01; 52(6):713-20. PubMed ID: 10848875
    [Abstract] [Full Text] [Related]

  • 4. Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity.
    Pincelli AI, Rigamonti AE, Scacchi M, Cella SG, Cappa M, Cavagnini F, Müller EE.
    Eur J Endocrinol; 2003 Feb 01; 148(2):237-43. PubMed ID: 12590644
    [Abstract] [Full Text] [Related]

  • 5. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M, Tassone F, Gianotti L, Lanfranco F, Grottoli S, Arvat E, Muller EE, Ghigo E.
    J Clin Endocrinol Metab; 2001 Jan 01; 86(1):167-71. PubMed ID: 11231996
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
    Rigamonti AE, Marazzi N, Cella SG, Cattaneo L, Müller EE.
    J Endocrinol; 1998 Feb 01; 156(2):341-8. PubMed ID: 9518881
    [Abstract] [Full Text] [Related]

  • 7. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P, Isidro L, Leal-Cerro A, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Apr 01; 56(4):487-92. PubMed ID: 11966741
    [Abstract] [Full Text] [Related]

  • 8. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L, Maccario M, Lanfranco F, Ramunni J, Di Vito L, Grottoli S, Muller EE, Ghigo E, Arvat E.
    J Clin Endocrinol Metab; 2000 Oct 01; 85(10):3604-8. PubMed ID: 11061509
    [Abstract] [Full Text] [Related]

  • 9. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa.
    Ghigo E, Arvat E, Gianotti L, Nicolosi M, Valetto MR, Avagnina S, Bellitti D, Rolla M, Müller EE, Camanni F.
    Biol Psychiatry; 1994 Nov 15; 36(10):689-95. PubMed ID: 7880938
    [Abstract] [Full Text] [Related]

  • 10. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state.
    Broglio F, Gianotti L, Destefanis S, Fassino S, Abbate Daga G, Mondelli V, Lanfranco F, Gottero C, Gauna C, Hofland L, Van der Lely AJ, Ghigo E.
    Clin Endocrinol (Oxf); 2004 May 15; 60(5):592-9. PubMed ID: 15104562
    [Abstract] [Full Text] [Related]

  • 11. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
    Leal-Cerro A, Soto A, Martínez MA, Alvarez P, Isidro L, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Dec 15; 57(6):745-9. PubMed ID: 12460324
    [Abstract] [Full Text] [Related]

  • 12. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF, Hindmarsh PC, Brook CG.
    Clin Endocrinol (Oxf); 1997 Nov 15; 47(5):537-47. PubMed ID: 9425393
    [Abstract] [Full Text] [Related]

  • 13. Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide.
    Rigamonti AE, Cavallera G, Bonomo S, Deghenghi R, Locatelli V, Cella SG, Müller EE.
    Eur J Endocrinol; 2001 Nov 15; 145(5):635-44. PubMed ID: 11720883
    [Abstract] [Full Text] [Related]

  • 14. GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide.
    Rigamonti AE, Bonomo SM, Cella SG, Müller EE.
    J Endocrinol; 2002 Sep 15; 174(3):387-94. PubMed ID: 12208658
    [Abstract] [Full Text] [Related]

  • 15. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E, Gianotti L, Arvat E, Ramunni J, Valetto MR, Broglio F, Rolla M, Cavagnini F, Müller EE.
    J Clin Endocrinol Metab; 1999 Jan 15; 84(1):285-90. PubMed ID: 9920097
    [Abstract] [Full Text] [Related]

  • 16. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S, Razzore P, Arvat E, Oleandri SE, Rossetto R, Ciccarelli E, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Nov 15; 20(10):597-602. PubMed ID: 9438917
    [Abstract] [Full Text] [Related]

  • 17. Aspects of the neuroendocrine control of somatotropic function in calorically restricted dogs and patients with eating disorders: studies with cholinergic drugs.
    Müller EE, Rolla M.
    Psychiatry Res; 1996 Apr 16; 62(1):51-63. PubMed ID: 8739115
    [Abstract] [Full Text] [Related]

  • 18. Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(1-44)-induced GH secretion in anorexia nervosa.
    Tamai H, Komaki G, Matsubayashi S, Kobayashi N, Mori K, Nakagawa T, Truong MP, Walter RM, Kumagai LF.
    J Clin Endocrinol Metab; 1990 Mar 16; 70(3):738-41. PubMed ID: 2106528
    [Abstract] [Full Text] [Related]

  • 19. The activity of GH/IGF-I axis in anorexia nervosa and in obesity: a comparison with normal subjects and patients with hypopituitarism or critical illness.
    Gianotti L, Broglio F, Ramunni J, Lanfranco F, Gauna C, Benso A, Zanello M, Arvat E, Ghigo E.
    Eat Weight Disord; 1998 Jun 16; 3(2):64-70. PubMed ID: 10728152
    [Abstract] [Full Text] [Related]

  • 20. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998 Jun 16; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.